Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Heron Therapeutics (HRTX)

Heron Therapeutics (HRTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 187,877
  • Shares Outstanding, K 188,537
  • Annual Sales, $ 154,900 K
  • Annual Income, $ -20,200 K
  • EBIT $ -3 M
  • EBITDA $ 0 M
  • 60-Month Beta 1.26
  • Price/Sales 1.18
  • Price/Cash Flow N/A
  • Price/Book 13.34
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.08
  • Most Recent Earnings $-0.05 on 11/04/25
  • Next Earnings Date 05/05/26
  • Annual Dividend & Yield (Fwd) 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Drugs

Options Overview Details

View History
  • Implied Volatility 217.59% (-198.20%)
  • Historical Volatility 68.59%
  • IV Percentile 60%
  • IV Rank 22.26%
  • IV High 772.50% on 11/20/25
  • IV Low 58.66% on 07/16/25
  • Expected Move (DTE 9) 0.2975 (30.11%)
  • Put/Call Vol Ratio 0.05
  • Today's Volume 233
  • Volume Avg (30-Day) 231
  • Put/Call OI Ratio 0.05
  • Today's Open Interest 13,412
  • Open Int (30-Day) 13,435
  • Expected Range 0.6907 to 1.2857

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate -0.02
  • Number of Estimates 2
  • High Estimate -0.01
  • Low Estimate -0.03
  • Prior Year 0.01
  • Growth Rate Est. (year over year) -300.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.9092 +8.69%
on 03/09/26
1.3300 -25.70%
on 02/26/26
-0.2818 (-22.19%)
since 02/10/26
3-Month
0.9092 +8.69%
on 03/09/26
1.5750 -37.26%
on 01/09/26
-0.3818 (-27.87%)
since 12/10/25
52-Week
0.9092 +8.69%
on 03/09/26
2.6100 -62.14%
on 05/06/25
-1.2318 (-55.49%)
since 03/10/25

Most Recent Stories

More News
Heron Therapeutics: Q4 Earnings Snapshot

Heron Therapeutics: Q4 Earnings Snapshot

HRTX : 0.9882 (-0.83%)
Heron Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results

– ZYNRELEF ® and APONVIE ® Drive 65% Year-Over-Year Net Revenue Growth in Acute Care Franchise – Achieved $154.9 Million in 2025 Net Revenue – Issues Full-Year 2026 Net Revenue Guidance...

HRTX : 0.9882 (-0.83%)
Heron Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, February 26, 2026

CARY, N.C., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Heron Therapeutics, Inc. (Nasdaq: HRTX) (“Heron” or the “Company”), a commercial-stage biotechnology company, today announced that the Company will...

HRTX : 0.9882 (-0.83%)
Heron Therapeutics Announces Preliminary, Unaudited Q4 and Full-Year 2025 Net Revenue; ZYNRELEF® Largest Contributor to Q4 Growth

CARY, N.C., Jan. 09, 2026 (GLOBE NEWSWIRE) -- Heron Therapeutics, Inc. (Nasdaq: HRTX) (“Heron” or the “Company”), a commercial-stage biotechnology company, today announced preliminary, unaudited...

HRTX : 0.9882 (-0.83%)
Heron Therapeutics Announces Inclusion of APONVIE® (aprepitant) Injectable Emulsion in the Newly Released Fifth Consensus Guidelines for the Management of Postoperative Nausea and Vomiting (PONV)

APONVIE, an aprepitant product, highlighted as the only FDA-approved IV formulation Neurokinin-1 (“NK-1”) antagonist indicated for the prevention of PONV in adults, with a long half-life and quicker...

HRTX : 0.9882 (-0.83%)
Heron Therapeutics: Q3 Earnings Snapshot

Heron Therapeutics: Q3 Earnings Snapshot

HRTX : 0.9882 (-0.83%)
Heron Therapeutics Announces Q3 2025 Financial Results and Highlights Commercial Progress

Generated Q3 2025 Net Revenue of $38.2 million and year-to-date revenue of $114.3 million; reaffirmed 2025 Net Revenue Guidance of $153 million - $163 million and adjusted EBITDA of $9.0 - $13.0 million...

HRTX : 0.9882 (-0.83%)
Heron Therapeutics Announces Appointment of Thomas Cusack to Board of Directors

CARY, N.C., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Heron Therapeutics, Inc. (Nasdaq: HRTX) (“Heron” or the “Company”), a commercial-stage biotechnology company, today announced the appointment of...

HRTX : 0.9882 (-0.83%)
Heron Therapeutics to Report Third Quarter 2025 Financial Results on Tuesday, November 4, 2025

CARY, N.C., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Heron Therapeutics, Inc. (Nasdaq: HRTX) (“Heron” or the “Company”), a commercial-stage biotechnology company, today announced that the Company will...

HRTX : 0.9882 (-0.83%)
Heron Therapeutics Approves Stock Issuance Proposals

Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Heron Therapeutics...

HRTX : 0.9882 (-0.83%)

Business Summary

Heron Therapeutics Inc. is a specialty pharmaceutical company. The company is developing products using its proprietary Biochronomer (TM) polymer-based drug delivery platform. Its product portfolio includes APF530, is being developed for the prevention of acute chemotherapy-induced nausea and vomiting....

See More

Key Turning Points

3rd Resistance Point 1.1117
2nd Resistance Point 1.0783
1st Resistance Point 1.0333
Last Price 0.9882
1st Support Level 0.9549
2nd Support Level 0.9215
3rd Support Level 0.8765

See More

52-Week High 2.6100
Fibonacci 61.8% 1.9603
Fibonacci 50% 1.7596
Fibonacci 38.2% 1.5589
Last Price 0.9882
52-Week Low 0.9092

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar